Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?

Detalhes bibliográficos
Autor(a) principal: Cavalcante, Glensimon Souza Silva
Data de Publicação: 2022
Outros Autores: Santos, Maria Conceição Santana dos, Braga, Mirelle de Sousa, Furtado, Gisele Rosada Dônola, Pereira, Krisley Rodrigues Lima, Lessa, Erika Elita Araújo, Barbosa, Kledson Lopes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/33562
Resumo: In addition to chronic diseases and empirical therapies against COVID-19, other factors are responsible for the high mortality rate associated with COVID-19. The objective of this study was to verify whether the exacerbated synthesis of inflammatory markers resulting from COVID-19 could compromise patients with coronavirus. The bibliographic research was performed in the Pubmed, LILACS, and SciELO databases between December 2020 and July 2021. For this study, the terms "COVID-19," "Biomarkers," "SARS-COV-2," and “Coronavirus 2019" are in advanced mode to gather the best evidence for the proposal of this manuscript. In the present construct, it is argued that COVID-19 increases the susceptibility of patients to a high stage of inflammation, increasing the virulence factors of the virus and its dissemination through the human body, where the synthesis of inflammatory factors plays a crucial role in the worsening of the cases. The virulence of the virus can be decreased by correcting the synthesis of these inflammatory markers, as it can prevent a less ineffective immune response and even increase the resistance of patients. Consequently, clinical trials in this direction should be carried out from the perspective of modulating responses at the molecular level, to find out how they work and how the underexpression of inflammatory cytokines may reduce the aggravation of patients with coronavirus.
id UNIFEI_b0f41e91598739528bc582ae1f635402
oai_identifier_str oai:ojs.pkp.sfu.ca:article/33562
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?¿La síntesis exacerbada de marcadores inflamatorios en COVID-19 puede afectar la respuesta a los tratamientos en pacientes con coronavirus?A síntese exacerbada de marcadores inflamatórios na COVID-19 pode prejudicar a resposta aos tratamentos em pacientes com coronavírus?COVID-19PandemiaSARS-CoV-2Marcadores inflamatórios.COVID-19PandemiaSARS-CoV-2Marcadores inflamatorios.COVID-19PandemicSARS-CoV-2Inflammatory markers.In addition to chronic diseases and empirical therapies against COVID-19, other factors are responsible for the high mortality rate associated with COVID-19. The objective of this study was to verify whether the exacerbated synthesis of inflammatory markers resulting from COVID-19 could compromise patients with coronavirus. The bibliographic research was performed in the Pubmed, LILACS, and SciELO databases between December 2020 and July 2021. For this study, the terms "COVID-19," "Biomarkers," "SARS-COV-2," and “Coronavirus 2019" are in advanced mode to gather the best evidence for the proposal of this manuscript. In the present construct, it is argued that COVID-19 increases the susceptibility of patients to a high stage of inflammation, increasing the virulence factors of the virus and its dissemination through the human body, where the synthesis of inflammatory factors plays a crucial role in the worsening of the cases. The virulence of the virus can be decreased by correcting the synthesis of these inflammatory markers, as it can prevent a less ineffective immune response and even increase the resistance of patients. Consequently, clinical trials in this direction should be carried out from the perspective of modulating responses at the molecular level, to find out how they work and how the underexpression of inflammatory cytokines may reduce the aggravation of patients with coronavirus.Además de las enfermedades crónicas y el uso de terapias empíricas contra la COVID-19, se cree que otros factores son responsables de la alta tasa de mortalidad asociada con la COVID-19. El objetivo de este estudio fue verificar si la síntesis exacerbada de marcadores inflamatorios resultante de la COVID-19 podría comprometer a los pacientes con coronavirus. La búsqueda bibliográfica se realizó en las bases de datos Pubmed, LILACS y SciELO entre diciembre de 2020 y julio de 2021. Para este estudio se utilizaron los términos “COVID-19”, “Biomarcadores”, “SARS-COV-2” y “Coronavirus 2019” están en modo avanzado para recopilar la mejor evidencia para la propuesta de este manuscrito. En el presente constructo se argumenta que el COVID-19 aumenta la susceptibilidad de los pacientes a un estadio alto de inflamación, aumentando los factores de virulencia del virus y su diseminación por el cuerpo humano, donde la síntesis de factores inflamatorios juega un papel crucial en la el empeoramiento de los síntomas casos. La virulencia del virus se puede disminuir corrigiendo la síntesis de estos marcadores inflamatorios, ya que se puede evitar una respuesta inmune menos ineficaz e incluso aumentar la resistencia de los pacientes. En consecuencia, los ensayos clínicos en esta dirección deberían realizarse desde la perspectiva de modular las respuestas a nivel molecular, para conocer cómo actúan y cómo la infraexpresión de las citocinas inflamatorias puede reducir el agravamiento de los pacientes con coronavirus.Além das doenças crônicas e do uso de terapias empíricas contra a COVID-19, acredita-se que outros fatores podem ser responsáveis pela alta taxa de mortalidade associada à COVID-19. O objetivo deste estudo foi verificar se a síntese exacerbada de marcadores inflamatórios decorrentes da COVID-19 poderiam comprometer os pacientes com coronavirus. A pesquisa bibliográfica foi realizada nas bases de dados Pubmed, LILACS e SciELO entre dezembro de 2020 e julho de 2021. Para este estudo, os termos "COVID-19", "Biomarcadores", "SARS-COV-2" e "Coronavírus 2019" foram usados em modo avançado para reunir as melhores evidências para a proposta deste manuscrito. No presente constructo, argumenta-se que a COVID-19 aumenta a susceptibilidade dos pacientes a um elevado estágio de inflamação, aumentando os fatores de virulência do vírus e sua disseminação pelo corpo humano, onde a síntese de fatores inflamatórios desempenha papel crucial no agravamento dos casos. A virulência do vírus pode ser diminuída corrigindo a síntese desses marcadores inflamatórios, pois pode prevenir uma resposta imunológica menos ineficaz e ainda aumentar a resistência dos pacientes. Consequentemente, os ensaios clínicos nesse sentido devem ser realizados sobre a perspectiva de modular as respostas a nível molecular, para descobrir como elas atuam e como a subexpressão de citocinas inflamatórias pode reduzir a agravamento dos pacientes com coronavírus.Research, Society and Development2022-08-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3356210.33448/rsd-v11i11.33562Research, Society and Development; Vol. 11 No. 11; e337111133562Research, Society and Development; Vol. 11 Núm. 11; e337111133562Research, Society and Development; v. 11 n. 11; e3371111335622525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/33562/28490Copyright (c) 2022 Glensimon Souza Silva Cavalcante; Maria Conceição Santana dos Santos; Mirelle de Sousa Braga; Gisele Rosada Dônola Furtado; Krisley Rodrigues Lima Pereira; Erika Elita Araújo Lessa; Kledson Lopes Barbosahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCavalcante, Glensimon Souza Silva Santos, Maria Conceição Santana dos Braga, Mirelle de Sousa Furtado, Gisele Rosada Dônola Pereira, Krisley Rodrigues Lima Lessa, Erika Elita Araújo Barbosa, Kledson Lopes 2022-09-05T13:24:46Zoai:ojs.pkp.sfu.ca:article/33562Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:49:10.437264Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
¿La síntesis exacerbada de marcadores inflamatorios en COVID-19 puede afectar la respuesta a los tratamientos en pacientes con coronavirus?
A síntese exacerbada de marcadores inflamatórios na COVID-19 pode prejudicar a resposta aos tratamentos em pacientes com coronavírus?
title Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
spellingShingle Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
Cavalcante, Glensimon Souza Silva
COVID-19
Pandemia
SARS-CoV-2
Marcadores inflamatórios.
COVID-19
Pandemia
SARS-CoV-2
Marcadores inflamatorios.
COVID-19
Pandemic
SARS-CoV-2
Inflammatory markers.
title_short Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
title_full Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
title_fullStr Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
title_full_unstemmed Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
title_sort Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
author Cavalcante, Glensimon Souza Silva
author_facet Cavalcante, Glensimon Souza Silva
Santos, Maria Conceição Santana dos
Braga, Mirelle de Sousa
Furtado, Gisele Rosada Dônola
Pereira, Krisley Rodrigues Lima
Lessa, Erika Elita Araújo
Barbosa, Kledson Lopes
author_role author
author2 Santos, Maria Conceição Santana dos
Braga, Mirelle de Sousa
Furtado, Gisele Rosada Dônola
Pereira, Krisley Rodrigues Lima
Lessa, Erika Elita Araújo
Barbosa, Kledson Lopes
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Cavalcante, Glensimon Souza Silva
Santos, Maria Conceição Santana dos
Braga, Mirelle de Sousa
Furtado, Gisele Rosada Dônola
Pereira, Krisley Rodrigues Lima
Lessa, Erika Elita Araújo
Barbosa, Kledson Lopes
dc.subject.por.fl_str_mv COVID-19
Pandemia
SARS-CoV-2
Marcadores inflamatórios.
COVID-19
Pandemia
SARS-CoV-2
Marcadores inflamatorios.
COVID-19
Pandemic
SARS-CoV-2
Inflammatory markers.
topic COVID-19
Pandemia
SARS-CoV-2
Marcadores inflamatórios.
COVID-19
Pandemia
SARS-CoV-2
Marcadores inflamatorios.
COVID-19
Pandemic
SARS-CoV-2
Inflammatory markers.
description In addition to chronic diseases and empirical therapies against COVID-19, other factors are responsible for the high mortality rate associated with COVID-19. The objective of this study was to verify whether the exacerbated synthesis of inflammatory markers resulting from COVID-19 could compromise patients with coronavirus. The bibliographic research was performed in the Pubmed, LILACS, and SciELO databases between December 2020 and July 2021. For this study, the terms "COVID-19," "Biomarkers," "SARS-COV-2," and “Coronavirus 2019" are in advanced mode to gather the best evidence for the proposal of this manuscript. In the present construct, it is argued that COVID-19 increases the susceptibility of patients to a high stage of inflammation, increasing the virulence factors of the virus and its dissemination through the human body, where the synthesis of inflammatory factors plays a crucial role in the worsening of the cases. The virulence of the virus can be decreased by correcting the synthesis of these inflammatory markers, as it can prevent a less ineffective immune response and even increase the resistance of patients. Consequently, clinical trials in this direction should be carried out from the perspective of modulating responses at the molecular level, to find out how they work and how the underexpression of inflammatory cytokines may reduce the aggravation of patients with coronavirus.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-24
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/33562
10.33448/rsd-v11i11.33562
url https://rsdjournal.org/index.php/rsd/article/view/33562
identifier_str_mv 10.33448/rsd-v11i11.33562
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/33562/28490
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 11; e337111133562
Research, Society and Development; Vol. 11 Núm. 11; e337111133562
Research, Society and Development; v. 11 n. 11; e337111133562
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052837355585536